Business UpdateMay 8, 2026, 10:33 AM
PatentVest Releases Report on Triple-Agonist Obesity Drug Race
AI Summary
PatentVest, a division of MDB Capital Holdings, has released a new report titled "The Triple-Agonist Race," providing a strategic analysis of the rapidly evolving obesity-drug landscape. The report highlights the market's transition beyond first-generation GLP-1 therapies, emphasizing the growing importance of intellectual property positioning, delivery systems, and long-term market control. It identifies 27 global triple-agonist programs and discusses how IP strategy and platform design will define the next phase of competition.
Key Highlights
- PatentVest's report analyzes 27 global triple-agonist programs in the obesity drug market.
- The study highlights the shift beyond first-generation GLP-1 therapies to IP strategy, receptor-ratio engineering, and delivery platforms.
- Key industry leaders include Eli Lilly, Novo Nordisk, Pfizer, Roche, and Sanofi, alongside emerging players.
- China accounts for a significant share of global triple-agonist development activity.
- IP dynamics are transitioning from receptor discovery to formulation control, delivery systems, and method-of-use claims.
- Companies like Sanofi, without visible clinical programs, may hold significant latent IP positions.
Price Impact
More from MDBH